AUTHOR=Tao Xuemei , Xu Changjing , Zhong Xiaoyan , Mou Yao , Li Jingwei , Yang Xuping , Huang Yilan 

TITLE=Real-world Biapenem vs. Meropenem in the treatment of severe community-acquired pneumonia in children: A propensity score matching analysis

JOURNAL=Frontiers in Pediatrics

VOLUME=Volume 10 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2022.1047595

DOI=10.3389/fped.2022.1047595

ISSN=2296-2360

ABSTRACT=Objective: Biapenem has been poorly studied in children. To compare effectiveness and safety of biapenem and meropenem in the real world. Methods: We retrospectively evaluated 915 children with severe community-acquired pneumonia (SCAP) who were treated with biapenem or meropenem from August 2018 to June 2022. Propensity-score matching analysis was performed with a 1:1 ratio to reduce the real-life baseline difference between the two groups. Results: After propensity score matching, 416 patients were included in the analysis (biapenem:meropenem=1:1). For the biapenem group and meropenem group, the effective rates were 90.4% and 90.9%, respectively (p=1.0) and the incidence of adverse reactions were 7.7% and 7.2%%, respectively (p=1.0). There were no statistical differences between the two groups. Conclusion: Biapenem is as effective and safe as meropenem in the treatment of children with SCAP.